Overview


Chronic myeloid leukaemia (CML) is a type of cancer that begins in the bone marrow's blood-forming cells. Adults are the ones who get it the most, and children are the ones who get it the least. Chronic myeloid leukaemia commonly strikes people once they reach the age of 60. CML is a slow-growing cancer that can be treated with tyrosine kinase inhibitors, chemotherapy, or a bone marrow transplant.
The survival rate for this kind of leukaemia has improved dramatically as a result of recent advancements in cancer treatment. Chemotherapy is predicted to have the largest market share in the chronic myeloid leukaemia treatment industry. Surgery and radiation therapy almost always remove, kill, or destroy cancer cells in a specific location in cancer patients, whereas chemotherapy operates throughout the body and produces better results.
Chemotherapy is required to eradicate cancer cells that have spread throughout the body. Surgery and radiation, on the other hand, only target and eliminate tumours that are located in a specific area. Because chronic myeloid leukaemia is a type of cancer that spreads throughout the body in a short amount of time, physicians choose to use chemotherapy to achieve better results.
The demand for medications to treat chronic myeloid leukaemia and its complications, such as blood malignancies, is on the rise. One of the most important elements that determines treatment choices is cost. As a result, the high cost of chronic myeloid leukaemia treatment pharmaceuticals is likely to stifle the worldwide chronic myeloid leukaemia treatment market's expansion.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Chronic Myeloid Leukemia Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Chronic Myeloid Leukemia Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

• Teva Pharmaceutical Industries Ltd.
• Hoffmann-La Roche Ltd.
• Novartis AG
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• Innovent Biologics, Inc.
• Pfizer, Inc.
• Viatris Inc. (Mylan N.V.)
• Lupin
• IL-YANG PHARM CO. LTD.
• Million Health Pharmaceuticals
(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Type
• Tyrosine Kinase Inhibitors
o Imatinib (Gleevac)
o Dasatinib (Sprycel)
o Nilotinib (Tasigna)
o Bosutinib (Bosulif)
o Ponatinib (Iclusig)
o Asciminib (Scemblix)
o Others
• Antimetabolites
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

• To provide with an exhaustive analysis on the Chronic Myeloid Leukemia Treatment Market By Drug Type, By Distribution Channel and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Chronic Myeloid Leukemia Treatment Market Variables, Trends
    • Scope
        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances
  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Chronic Myeloid Leukemia Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Chronic Myeloid Leukemia Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Chronic Myeloid Leukemia Treatment Market, By Drug Type Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Tyrosine Kinase Inhibitors
         1.1. Imatinib (Gleevac)
         1.2. Dasatinib (Sprycel)
         1.3. Nilotinib (Tasigna)
         1.4. Bosutinib (Bosulif)
         1.5. Ponatinib (Iclusig)
         1.6. Asciminib (Scemblix)
         1.7. Others
        2. Antimetabolites
        3. Others
  • 8.   Chronic Myeloid Leukemia Treatment Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
  • 9.   North America Chronic Myeloid Leukemia Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
           2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2022-2028
  • 10.   Latin America Chronic Myeloid Leukemia Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2022-2028
  • 11.   Europe Chronic Myeloid Leukemia Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Germany
          2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2022-2028
  • 12.   Asia Pacific Chronic Myeloid Leukemia Treatment Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
  • 13.   Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2022-2028
  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •    1. Teva Pharmaceutical Industries Ltd.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
         2. Hoffmann-La Roche Ltd.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Novartis AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Bristol-Myers Squibb Company
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Takeda Pharmaceutical Company Limited
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
         6. Innovent Biologics, Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
         7. Pfizer, Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
           8. Viatris Inc. (Mylan N.V.)
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Lupin
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
          10.IL-YANG PHARM CO. LTD.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11.Million Health Pharmaceuticals
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12.Celon Labs
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients